These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28393712)

  • 1. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.
    Ohno Y; Tokudome K
    CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy].
    Tokudome K; Shimizu S; Serikawa T; Ohno Y
    Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.
    Tokudome K; Okumura T; Shimizu S; Mashimo T; Takizawa A; Serikawa T; Terada R; Ishihara S; Kunisawa N; Sasa M; Ohno Y
    Sci Rep; 2016 Jun; 6():27420. PubMed ID: 27265781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release.
    Tokudome K; Okumura T; Terada R; Shimizu S; Kunisawa N; Mashimo T; Serikawa T; Sasa M; Ohno Y
    Front Pharmacol; 2016; 7():210. PubMed ID: 27471467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
    Shi J; Zhou F; Wang LK; Wu GF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal and spatial changes in synaptic vesicle glycoprotein 2A (SV2A) under kainic acid induced epileptogenesis: An autoradiographic study.
    Pazarlar BA; Madsen CA; Oyar EÖ; Eğilmez CB; Mikkelsen JD
    Epilepsy Res; 2022 Jul; 183():106926. PubMed ID: 35526328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hippocampal low-frequency stimulation increased SV2A expression and inhibited the seizure degree in pharmacoresistant amygdala-kindling epileptic rats.
    Wang L; Shi J; Wu G; Zhou F; Hong Z
    Epilepsy Res; 2014 Nov; 108(9):1483-91. PubMed ID: 25205164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling.
    Ohno Y; Ishihara S; Terada R; Kikuta M; Sofue N; Kawai Y; Serikawa T; Sasa M
    Biochem Biophys Res Commun; 2009 Dec; 390(3):415-20. PubMed ID: 19751703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain.
    Mendoza-Torreblanca JG; García-Cruz ME; Sánchez-Cruz I; Gomez-Gonzalez B; Juárez-Méndez S; Gómez-Lira G
    Neuroscience; 2019 Nov; 419():108-120. PubMed ID: 31520710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.
    Toering ST; Boer K; de Groot M; Troost D; Heimans JJ; Spliet WG; van Rijen PC; Jansen FE; Gorter JA; Reijneveld JC; Aronica E
    Epilepsia; 2009 Jun; 50(6):1409-18. PubMed ID: 19220410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
    Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H
    CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.
    Menten-Dedoyart C; Serrano Navacerrada ME; Bartholome O; Sánchez Gil J; Neirinckx V; Wislet S; Becker G; Plenevaux A; Van den Ackerveken P; Rogister B
    PLoS One; 2016; 11(11):e0166525. PubMed ID: 27861538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatio-Temporal Alterations in Synaptic Density During Epileptogenesis in the Rat Brain.
    Mikkelsen JD; Aripaka SS; Bascuñana P; Bankstahl M; Bankstahl JP; Pazarlar BA
    Neuroscience; 2022 Sep; 499():142-151. PubMed ID: 35878719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.
    Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG
    Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
    de Groot M; Toering ST; Boer K; Spliet WG; Heimans JJ; Aronica E; Reijneveld JC
    Neuro Oncol; 2010 Mar; 12(3):265-73. PubMed ID: 20167814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.